Accuray Inc. announces practice milestone using its CyberKnife system.
Accuray, Inc., a radiation oncology company based in Sunnyvalle, California, recently announced that Anova Cancer Care has performed an impressive 1,000 prostate cancer treatments using the company’s CyberKnife system. CyberKnife is a robotically-controlled radiosurgery device that delivers extremely high doses of radiation to tumors with little to no side effects. It is an alternative or complimentary option to more traditional forms of cancer treatment including radiation therapy, chemotherapy and surgical techniques.
Rick H. from Denver, one of the 1,000 patients, was recently diagnosed with prostate cancer and was featured in the release. “I lead a busy life, including owning a business, so when I learned it was a non-invasive approach which would precisely target my tumor, I knew it was the right choice for me,” said Rick.
Anova is Colorado’s only full-time CyberKnife practice and a world leader in prostate cancer treatment.
View Treatment Info
Lecture will discuss his success with CyberKnife
Anova Cancer Care’s Chief Oncologist was invited to the Annual Academic Meeting of Radiation Oncology Oct. 29 in Chengdu, Sichuan, China. During the meeting he discussed Anova’s CyberKnife technology and prostate cancer treatment, as well as Anova experience treating more than 1,000 prostate cancer patients with CyberKnife stereotactic body radiation therapy.
Learn more about prostate cancer CyberKnife treatment
Anova is a proud sponsor of the 2015 Don’t Fear the Finger golf outing benefitting the Please Save Another (PSA) foundation and those struggling with stage 4 prostate cancer.
What: Fifth Annual Don’t Fear the Finger golf outing
When: September 10, 2015
About: The annual fundraiser is dedicated to all the men (and their families) who face or will face prostate cancer. The event is organized by Please Save Another, a 501(C)(3) volunteer foundation.
Clinical trial demonstrates CyberKnife effectiveness for prostate cancer
A ZeroCancer news roundup highlights the latest clinical trial study following the Registry for Prostate Cancer Radiosurgery, launched in July 2010, which follows the overall treatment effectiveness of CyberKnife for prostate cancer. The Frontiers in Oncology study, which includes Anova Cancer Care patients, follows more than 2,700 men from 45 participating locations. The study reported that CyberKnife treatment was effective in treating prostate cancer as well as preserving sexual health with no significant side effects.
ZeroCancer news roundup
Frontiers in Oncology study
Anova study was presented at the American College of Radiation Oncology/Radiosurgery Society
Anova’s Chief of Radiosurgery and Medical Director presented a study showing the promise of stereotactic body radiotherapy (SBRT) on large prostate cancers at a national meeting in DC.
The study, “Large Prostate Volumes Treated With Autonomous Continuous Image Guidance Stereotactic Body Radiation Therapy For Prostate Cancer,” was presented during a joint meeting of the American College of Radiation Oncology (ACRO) and the Radiosurgery Society (RSS) meeting held May 14-16 in Washington, D.C.
Read the full study abstract
Learn more about the ACRO 2015 Annual Meeting
Anova doctors work to reduce insurance costs by proving CyberKnife treatment’s efficacy
With all the recent changes taking place with regard to healthcare reform and cost, you might consider Anova Cancer Care the “poster child” for healthcare reform. Anova Cancer Care specializes in CyberKnife, a new radiosurgery procedure that uses targeted radiation to eradicate cancer cells. Since the procedure is new, there are many insurers who aren’t reimbursing individuals for this treatment.
Confident about CyberKnife success and how the technology can help cancer patients, Anova physicians worked diligently to make it available and cost efficient for patients.
Continue Reading the Denver Business Journal Article